Related Experiment Video

Updated: Sep 13, 2025

Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

8.0K

Early and Precise: Treating HRR Alterations in Hormone-Sensitive Prostate Cancer

Laura S Graham1, Evan Y Yu2

  • 1Division of Medical Oncology, University of Colorado Cancer Center, Aurora, Colorado.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|July 31, 2025
PubMed

Insights

Patients with prostate cancer and homologous recombination repair (HRR) alterations have poorer prognoses. Early PARP inhibitor use shows promise, particularly for BRCA-mutated cancers, but further research is needed for non-BRCA alterations.

Area of Science:

  • Oncology
  • Genetics
  • Pharmacology

Background:

  • Prostate cancer patients with homologous recombination repair (HRR) alterations experience worse clinical outcomes.
  • Harnessing HRR alterations for targeted therapy is a key area in prostate cancer research.

Purpose of the Study:

  • To review the current understanding of PARP inhibitors in prostate cancer.
  • To highlight the efficacy in BRCA-mutated cancers and the uncertainties in non-BRCA alterations.
  • To emphasize the need for further clinical trials and personalized treatment strategies.

Main Methods:

  • Literature review of clinical trials and studies on PARP inhibitors in prostate cancer.
  • Analysis of outcomes based on HRR alteration status (BRCA vs. non-BRCA).
  • Discussion of treatment sequencing and optimal timing of PARP inhibitors.

Main Results:

  • Early use of PARP inhibitors is a promising strategy, particularly for prostate cancer with BRCA mutations.
  • The benefits and optimal use of PARP inhibitors for non-BRCA HRR alterations are not yet clearly defined.
  • Significant heterogeneity exists in treatment response across different HRR alterations.

Conclusions:

  • PARP inhibitors represent a significant advancement in treating prostate cancer with HRR alterations.
  • Further well-designed clinical trials are essential to clarify the role of PARP inhibitors in non-BRCA mutated cancers.
  • Personalized treatment discussions considering specific HRR alterations are crucial for optimizing patient outcomes.

More Related Videos

Detection and Isolation of Cancer in Prostate Biopsies Using Stimulated Raman Histology and Artificial Intelligence08:05

Detection and Isolation of Cancer in Prostate Biopsies Using Stimulated Raman Histology and Artificial Intelligence

Published on: June 10, 2025

670
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.3K

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
254
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
510
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
259
Hazard Ratio01:12

Hazard Ratio

The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
251
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
225
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
254